Analyst Tim Anderson from Bank of America Securities reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at $1,000.00.
Tim Anderson’s rating is based on Eli Lilly & Co’s robust growth potential, particularly in the GLP-1 obesity category, where the company is a leading player. The analyst notes that Eli Lilly’s strong position in this market is supported by various competitive advantages that are expected to sustain its market share in the long term.
Additionally, the company’s financial outlook remains positive with only minor adjustments to revenue and EPS estimates through 2025 and beyond. The price objective of $1,000 reflects confidence in the company’s future earnings, supported by key products like Mounjaro and Zepbound, and the promising prospects of orforglipron following successful trial results.
In another report released yesterday, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $975.00 price target.